Effects of long-term treatment with carvedilol on myocardial blood flow in idiopathic dilated cardiomyopathy

Heart

Volumn 93, Issue 7, 2007, Pages 808-813

  Neglia, Danilo ^a   De Maria, Renata ^a   Masi, Stefano ^b   Gallopin, Michela ^c   Pisani, Patrizia ^a   Pardini, Silvia ^a   Gavazzi, Antonello ^d   L'Abbate, Antonio ^e   Parodi, Oberdan ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c MISERICORDIA E DOLCE HOSPITAL   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; CARVEDILOL; DIPYRIDAMOLE; NITROGEN 13; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; EXERCISE; EXERCISE TEST; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BLOOD FLOW; HUMAN; LONG TERM CARE; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

CARBAZOLES; CARDIOMYOPATHY, DILATED; CORONARY CIRCULATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROPANOLAMINES; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34347261707     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.095208     Document Type: Article

References (25)

1. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
2. Packer M, Coats AJS, Fowler MB, for the Carvedilol Prospective Randomized Cumulative Survival Study Group, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
3. Poole-Wilson PA, Swedberg K, Cleland JGF, for the COMET investigators, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
4. Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001;141:899-907.
5. Bristow MR. Why does the myocardium fail? Insights from basic science, Lancet 1998;352(Suppl 1):8-14.
6. Cleland JGF, Bristow M, Erdman E, et al. Beta-blocking agents in heart failure: should they be used and how? Eur Heart J 1996;17:1629-39.
7. Sponer G, Strain K, Bartsch W, et al. Vasodilatory action of carvedilol. J Cardiovasc Pharmacol 1992;19(Suppl 1):S5-11.
8. Yue TL, Ruffolo RR Jr, Feuerstein G. Antioxidant action of carvedilol: a potential role in treatment of heart failure. Heart Fail Rev 1999;4:39-51.
9. Cleland JG, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 2003;362:14-21.
10. Green P, Anshelevich M, Talreja A, et al. Long-term effects of carvedilol or metoprolol on left ventricular function in ischemic and nonischemic cardiomyopathy. Am J Cardiol 2005;95:1114-16.
11. Metra M, Narai M, Giubbini R, et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-87.
12. O'Keefe JH Jr, Magalski A, Stevens TL, et al. Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure. J Nucl Cardiol 2000;7:3-7.
13. Gerson MC, Craft LL, McGuire N, et al. Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol 2002;9:608-15.
14. Neglia D, Parodi O, Gallopin M, et al. Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. A quantitative assessment by positron emission tomography. Circulation 1995;92:796-804.
15. Neglia D, Michelassi C, Trivieri MG, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002;105:186-93.
16. Unverferth DV, Magorien RD, Lewis RP, et al. The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. Am Heart J 1983;105:176-9.
17. van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2000;35:19-28.
18. De Maria R, Gavazzi A, Sinagra G, et al. Long-term carvedilol treatment in idiopathic dilated cardiomyopathy: biological effects beyond pharmacological activity. J Am Coll Cardiol 2002;39(Suppl B):409B.
19. Gould KL. Identifying and measuring severity of coronary artery stenosis: quantitative coronary angiography and positron emission tomography. Circulation 1988;78:237-45.
20. Bøttcher M, Refsgaard J, Gøtzsche O, et al. Effect of carvedilol on microcirculatory and glucose metabolic regulation in patients with congestive heart failure secondary to ischemic cardiomyopathy. Am J Cardiol 2002;89:1388-93.
21. Treasure CB, Vita JA, Cox DA, et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 1990;81:772-9.
22. Duffy SJ, Castle SF, Harper RW, et al. Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation. Circulation 1999;100:1951-7.
23. Quyyumi AA, Dakak N, Andrews NP, et al. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995;92:320-6.
24. Buus NH, Bøttcher M, Hermansen F, et al. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 2001;104:2305-10.
25. Beanlands RS, Nahmias C, Gordon E, et al. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation 2000;102:2070-5.